2 Healthcare Stocks to Buy Ahead of the New Year

CRISPR Therapeutics could soar on the back of significant pipeline progress next year. Vertex's slow and steady approach to diversifying its lineup should eventually pay off.

The Motley Fool • Dec 12, 2025

Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report?

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 10, 2025

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Investment Research • Dec 8, 2025

2 Stocks That Could Soar by 52% and 282%, According to Wall Street

CRISPR Therapeutics' approved medicine is making slow progress, but it has an exciting pipeline. Iovance Biotherapeutics is generating decent revenue, but it faces significant obstacles.

The Motley Fool • Dec 7, 2025

Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy

Crispr Therapeutics AG remains a Strong Buy, driven by forthcoming revenue following Casgevy's FDA/EMA approvals and a robust, expanding pipeline targeting high-value indications. CRSP's commercial launch of Casgevy is progressing, with their share of a $100M+ 2025 total revenue expectation, and significant growth expected into 2026. The pipeline's cardiovascular assets (CTX310/320) show promising early efficacy, with huge addressable markets and the potential to disrupt standard-of-care regimens.

Seeking Alpha • Dec 4, 2025

Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50%

Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it's one of her top holdings.

The Motley Fool • Nov 30, 2025

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research • Nov 25, 2025

3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential

Mid-cap stocks can come with risks, but also a ton of upside in the long run. The stocks listed here offer exciting growth opportunities across multiple industries.

The Motley Fool • Nov 21, 2025

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Eli Lilly has advanced in the triple-digits over three years, thanks to its weight loss drug portfolio. The following two biotech companies, due to the potential of their late-stage candidates, also could deliver a win for investors.

The Motley Fool • Nov 19, 2025

4 Struggling Stocks With “Harmless” Pullbacks

Subscribers to  Chart of the Week  received this commentary on Sunday, November 16.

Schaeffers Research • Nov 18, 2025